DE69428112T2 - Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen - Google Patents

Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen

Info

Publication number
DE69428112T2
DE69428112T2 DE69428112T DE69428112T DE69428112T2 DE 69428112 T2 DE69428112 T2 DE 69428112T2 DE 69428112 T DE69428112 T DE 69428112T DE 69428112 T DE69428112 T DE 69428112T DE 69428112 T2 DE69428112 T2 DE 69428112T2
Authority
DE
Germany
Prior art keywords
thymosin
interferon
don
patients
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428112T
Other languages
English (en)
Other versions
DE69428112D1 (de
Inventor
Paul B Chretien
Milton Mutchnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Alpha 1 Biomedicals Inc
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/027,500 external-priority patent/US6001799A/en
Application filed by Wayne State University, Alpha 1 Biomedicals Inc filed Critical Wayne State University
Publication of DE69428112D1 publication Critical patent/DE69428112D1/de
Application granted granted Critical
Publication of DE69428112T2 publication Critical patent/DE69428112T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69428112T 1993-03-05 1994-03-03 Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen Expired - Lifetime DE69428112T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,500 US6001799A (en) 1991-09-13 1993-03-05 Method of treating hepatitis C in non-responders to interferon treatment
PCT/US1994/002320 WO1994020131A1 (en) 1993-03-05 1994-03-03 Method of treating hepatitis c in non-responders to interferon treatment

Publications (2)

Publication Number Publication Date
DE69428112D1 DE69428112D1 (de) 2001-10-04
DE69428112T2 true DE69428112T2 (de) 2002-03-21

Family

ID=21838079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428112T Expired - Lifetime DE69428112T2 (de) 1993-03-05 1994-03-03 Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen

Country Status (17)

Country Link
EP (1) EP0687181B1 (de)
JP (1) JPH06279309A (de)
KR (1) KR100306024B1 (de)
CN (1) CN1072961C (de)
AT (1) ATE204760T1 (de)
AU (1) AU683248B2 (de)
CA (1) CA2157479C (de)
DE (1) DE69428112T2 (de)
DK (1) DK0687181T3 (de)
ES (1) ES2162862T3 (de)
FI (1) FI954127A (de)
GR (1) GR3037021T3 (de)
MY (1) MY121198A (de)
NO (1) NO320877B1 (de)
PT (1) PT687181E (de)
SG (1) SG64894A1 (de)
WO (1) WO1994020131A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
PT1311286E (pt) * 2000-08-07 2006-11-30 Sciclone Pharmaceuticals Inc Combinação farmacêutica que contém timosina e interferão pegilado para o tratamento do hepatite c
BRPI0408892A (pt) 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
EP2421970B1 (de) * 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmazeutische zusammensetzungen zur behandlung von nicht auf interferon ansprechende hcv-patienten
EP2427213B1 (de) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha-thymosin-peptide als impfstoffverstärker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
GR3037021T3 (en) 2002-01-31
SG64894A1 (en) 1999-05-25
JPH06279309A (ja) 1994-10-04
FI954127A0 (fi) 1995-09-04
KR100306024B1 (ko) 2001-11-30
ATE204760T1 (de) 2001-09-15
ES2162862T3 (es) 2002-01-16
CA2157479A1 (en) 1994-09-15
MY121198A (en) 2006-01-28
EP0687181A1 (de) 1995-12-20
NO953473D0 (no) 1995-09-04
DK0687181T3 (da) 2001-10-01
NO953473L (no) 1995-09-04
FI954127A (fi) 1995-09-04
WO1994020131A1 (en) 1994-09-15
CN1092322A (zh) 1994-09-21
DE69428112D1 (de) 2001-10-04
CA2157479C (en) 2000-08-08
AU683248B2 (en) 1997-11-06
KR960700741A (ko) 1996-02-24
EP0687181B1 (de) 2001-08-29
CN1072961C (zh) 2001-10-17
NO320877B1 (no) 2006-02-06
PT687181E (pt) 2002-01-30
AU6275994A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE69233607D1 (de) Peptide, die die zytotoxische T-Lymphozyte Antwort gegen Hepatitis-B-Virus induzieren
EP0616535A4 (de) Methode zur behandlung von varalen infektionen.
DE69428112T2 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
GR3024236T3 (en) Use of leukoregulin for the treatment of animals infected with an envelope-virus
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
ATE76302T1 (de) Verwendung von einer immunstimulanten biologisten substanz zur herstellung eines medikaments zur behandlung des menschlichen immunschwaechevirus.
MY109685A (en) Method for treating hepatitis b carriers with minimal disease
MX9708885A (es) Uso de ribavirin e interferon alfa para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition